Roles of prostaglandin E2 in the cochlea

Hearing Research

Volumn 276, Issue 1-2, 2011, Pages 27-33

  Nakagawa, Takayuki ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; PROSTAGLANDIN E RECEPTOR 1; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; VASCULOTROPIN;

CENTRAL NERVOUS SYSTEM; COCHLEA; COCHLEA BLOOD FLOW; DEGENERATIVE DISEASE; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR UPREGULATION; REVIEW; SENSORY NERVE CELL; SENSORY SYSTEM; SIGNAL TRANSDUCTION;

ANIMALS; CENTRAL NERVOUS SYSTEM; COCHLEA; DINOPROSTONE; HUMANS; MAMMALS; NEURONS, AFFERENT; PROTEIN ISOFORMS; RECEPTORS, PROSTAGLANDIN E; REGIONAL BLOOD FLOW; SIGNAL TRANSDUCTION;

EID: 79957966416     PISSN: 03785955     EISSN: 18785891     Source Type: Journal    
DOI: 10.1016/j.heares.2011.01.015     Document Type: Review

References (81)

1. Agarwal L., Pothier D.D. Vasodilators and vasoactive substances for idiopathic sudden sensorineural hearing loss. Cochrane Database Syst. Rev. 2009, 4:CD003422.
2. Ahmad A.S., Ahmad M., de Brum-Fernandes A.J., Doré S. Prostaglandin EP4 receptor agonist protects against acute neurotoxicity. Brain Res. 2005, 1066:71-77.
3. Ahmad A.S., Saleem S., Ahmad M., Dore S. Prostaglandin EP1 receptor contributes to excitotoxicity and focal ischemic brain damage. Toxicol. Sci. 2006, 89:265-270.
4. Ahmad M., Ahmad A.S., Zhuang H., Maruyama T., Narumiya S., Dore S. Stimulation of prostaglandin E2-EP3 receptors exacerbates stroke and excitotoxic injury. J. Neuroimmunol 2007, 184:172-179.
5. Ahn J.H., Kim M.R., Kim H.C. Therapeutic effect of lipoprostaglandin E1 on sudden hearing loss. Am. J. Otolaryngol. 2005, 26:245-248.
6. Andreasson K. Emerging roles of PGE2 receptors in models of neurological disease. Prostaglandins Other Lipid Mediat 2010, 91:104-112.
7. Bilson H.A., Mitchell D.L., Ashby B. Human prostaglandin EP3 receptor isoforms show different agonist-induced internalization patterns. FEBS Lett. 2004, 572:271-275.
8. Bradbury D., Clarke D., Seedhouse C., Corbett L., Stocks J., Knox A. Vascular endothelial growth factor induction by prostaglandin E2 in human airway smooth muscle cells is mediated by E prostanoid EP2/EP4 receptors and SP-1 transcription factor binding sites. J. Biol. Chem. 2005, 28:29993-30000.
9. Candelario-Jalil E., Slawik H., Ridelis I., Waschbisch A., Akundi R.S., Hüll M., Fiebich B.L. Regional distribution of the prostaglandin E2 receptor EP1 in the rat brain: accumulation in Purkinje cells of the cerebellum. J. Mol. Neurosci. 2005, 27(3):303-310.
10. Carrasco E., Casper D., Werner P. PGE(2) receptor EP1 renders dopaminergicneurons selectively vulnerable to low-level oxidative stress and direct PGE(2) neurotoxicity. J. Neurosci. Res. 2007, 85:3109-3117.
11. Chang S.H., Liu C.H., Wu M.T., Hla T. Regulation of vascular endothelial cell growth factor expression in mouse mammary tumor cells by the EP2 subtype of the prostaglandin E2 receptor. Prostaglandins Other Lipid Mediat 2005, 76:48-58.
12. Dey I., Lejeune M., Chadee K. Prostaglandin E2 receptor distribution and function in the gastrointestinal tract. Br. J. Pharmacol. 2006, 149:611-623.
13. Divangahi M., Desjardins D., Nunes-Alves C., Remold H.G., Behar S.M. Eicosanoid pathways regulate adaptive immunity to Mycobacterium tuberculosis. Nat. Immunol. 2010, 11(8):751-758.
14. Duan M., Agerman K., Ernfors P., Canlon B. Complementary roles of neurotrophin 3 and a N-methyl-D-aspartate antagonist in the protection of noise and aminoglycoside-induced ototoxicity. Proc. Natl. Acad. Sci. U S A 2000, 97(13):7597-7602.
15. Esaki Y., Li Y., Sakata D., Yao C., Segi-Nishida E., Matsuoka T., Fukuda K., Narumiya S. Dual roles of PGE2-EP4 signaling in mouse experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U S A 2010, 107(27):12233-12238.
16. Fortier M.A., Krishnaswamy K., Danyod G., Boucher-Kovalik S., Chapdalaine P. Apostgenomic integrated view of prostaglandins in reproduction: implications for other body systems. J. Physiol. Pharmacol. 2008, 59(Suppl. 1):65-89.
17. Fujioka M., Kanzaki S., Okano H.J., Masuda M., Ogawa K., Okano H. Proinflammatory cytokines expression in noise-induced damaged cochlea. J. Neurosci. Res. 2006, 83(4):575-583.
18. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001, 294:1871-1875.
19. Gagliardi M.C., Teloni R., Mariotti S., Bromuro C., Chiani P., Romagnoli G., Giannoni F., Torosantucci A., Nisini R. Endogenous PGE2 promotes the induction of human Th17 responses by fungal ß-glucan. J. Leukoc. Biol. 2010, 88(5):947-954.
20. Hakuba N., Gyo K., Yanagihara N., Mitani A., Kataoka K. Efflux of glutamate into the perilymph of the cochlea following transient ischemia in the gerbil. Neurosci. Lett. 1997, 230(1):69-71.
21. Hakuba N., Koga K., Gyo K., Usami S.-I., Tanaka K. Exacerbation of noise-induced hearing loss in mice lacking the glutamate transporter GLAST. J. Neurosci. 2000, 20(23):8750-8753.
22. Harris S.G., Padilla J., Koumas L., Ray D., Phipps R.P. Prostaglandins as modulators of immunity. Trends Immunol. 2002, 23:144-150.
23. Hasegawa H., Katoh H., Yamaguchi Y., Nakamura K., Futakawa S., Negishi M. Different membrane targeting of prostaglandin EP3 receptor isoforms dependent on their carboxy-terminal tail structures. FEBS Lett. 2000, 473(1):76-80.
24. Heinrich U.R., Brieger J., Selivanova O., Feltens R., Eimermacher A., Schäfer D., Mann W.J. COX-2 expression in the guinea pig cochlea is partly altered by moderate sound exposure. Neurosci. Lett. 2006, 394:121-126.
25. Heinrich U.R., Selivanova O., Schmidtmann I., Feltens R., Brieger J., Mann W.J. Noise exposure alters cyclooxygenase 1 (COX-1) and 5-lipoxygenase (5-LO) expression in the guinea pig cochlea. Acta Otolaryngol. 2010, 130(3):358-365.
26. Hirose K., Discolo C.M., Keasler J.R., Ransohoff R. Mononuclear phagocytes migrate into the murine cochlea after acoustic trauma. J. Comp. Neurol. 2005, 489(2):180-194.
27. Hristovska A.M., Rasmussen L.E., Hansen P.B., Nielsen S.S., Nüsing R.M., Narumiya S., Vanhoutte P., Skøtt O., Jensen B.L. Prostaglandin E2 induces vascular relaxation by E-prostanoid 4 receptor-mediated activation of endothelial nitric oxide synthase. Hypertension 2007, 50(3):525-530.
28. Hoshino T., Tabuchi K., Hirose Y., Uemaetomari I., Murashita H., Tobita T., Hara A. The non-steroidal anti-inflammatory drugs protect mouse cochlea against acoustic injury. Tohoku J. Exp. Med. 2008, 216:53-59.
29. Hori R., Nakagawa T., Sugimoto Y., Sakamoto T., Yamamoto N., Hamaguchi K., Ito J. Prostaglandin E receptor subtype EP4 agonist protects auditory hair cells against noise-induced trauma. Neuroscience 2009, 160:813-819.
30. Hori R., Nakagawa T., Yamamoto N., Hamaguchi K., Ito J. Role of prostaglandin E receptor subtypes EP2 and EP4 in autocrine and paracrine functions of vascular endothelial growth factor in the inner ear. BMC Neurosci. 2010, 11:35.
31. Huang N., Ashrafpour H., Levine R.H., Forrest C.R., Neligan P.C., Lipa J.E., Pang C.Y. Vasorelaxation effect and mechanism of action of vascular endothelial growth factor-165 in isolated perfused human skin flaps. J. Surg. Res. 2010, [Epub ahead of print].
32. Ikeda-Matsuo Y., Tanji H., Ota A., Hirayama Y., Uematsu S., Akira S., Sasaki Y. Microsomal prostaglandin E synthase-1 contributes to ischaemic excitotoxicity through prostaglandin E2 EP3 receptors. Br. J. Pharmacol. 2010, 160:847-859.
33. Inoue H., Takamori M., Shimoyama Y., Ishibashi H., Yamamoto S., Koshihara Y. Regulation by PGE2 of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts. Br. J. Pharmacol. 2002, 136(2):287-295.
34. Jain S., Chakraborty G., Raja R., Kale S., Kundu G.C. Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res. 2008, 68:7750-7759.
35. Jiang J., Ganesh T., Du Y., Thepchatri P., Rojas A., Lewis I., Kurtkaya S., Li L., Qui M., Serrano G., Shaw R., Sun A., Dingledine R. Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor. Proc. Natl. Acad. Sci. U S A 2010, 107:2307-2312.
36. Jin J., Shie F.S., Liu J., Wang Y., Davis J., Schantz A.M., Montine K.S., Montine T.J., Zhang J. Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associatedneurotoxicity inducedby aggregated alpha-synuclein. J. Neuroinflamm 2007, 4:2.
37. Kawano T., Anrather J., Zhou P., Park L., Wang G., Frys K.A., Kunz A., Cho S., Orio M., Iadecola C. Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat. Med. 2006, 12(2):225-229.
38. Kawata R., Urade Y., Tachibana M., Mizukoshi O. Prostaglandin synthesis by thecochlea. Prostaglandins 1988, 35:173-184.
39. Krause P., Bruckner M., Uermosi C., Singer E., Groettrup M., Legler D.F. Prostaglandin E2 enhances T cell proliferation by inducing the co-stimulatory molecules OX40L, CD70 and 4-1BBL on dendritic cells. Blood 2009, 113:2451-2460.
40. Legler D.F., Bruckner M., Uetz-von Allmen E., Krause P. Prostaglandin E2 at new glance: novel insights in functional diversity offer therapeutic chances. Int. J. Biochem. Cell Biol. 2010, 42(2):198-201.
41. Li J., Liang X., Wang Q., Breyer R.M., McCullough L., Andreasson K. Misoprostol, an anti-ulcer agent and PGE2 receptor agonist, protects against cerebral ischemia. Neurosci. Lett. 2008, 438(2):210-215.
42. Liang X., Wang Q., Shi J., Lokteva L., Breyer R.M., Montine T.J., Andreasson K. The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann. Neurol. 2008, 64(3):304-314.
43. Liu D., Wu L., Breyer R., Mattson M.P., Andreasson K. Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia. Ann. Neurol. 2005, 57(5):758-761.
44. Mandapathil M., Szczepanski M.J., Szajnik M., Ren J., Jackson E.K., Johnson J.T., Gorelik E., Lang S., Whiteside T.L. Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J. Biol. Chem. 2010, 285(36):27571-27580.
45. McCullough L., Wu L., Haughey N., Liang X., Hand T., Wang Q., Breyer R.M., Andreasson K. Neuroprotective function of the PGE2EP2 receptor in cerebral ischemia. J. Neurosci. 2004, 24(1):257-268.
46. Miller J.M., Brown J.N., Schacht J. 8-iso-prostaglandin F(2alpha), a product of noise exposure, reduces inner ear blood flow. Audiol. Neurootol. 2003, 8(4):207-221.
47. Montine T.J., Milatovic D., Gupta R.C., Valyi-Nagy T., Morrow J.D., Breyer R.M. Neuronal oxidative damage from activated innate immunity is EP2 receptor dependent. J. Neurochem. 2002, 83(2):463-470.
48. Moon S.K., Park R., Lee H.Y., Nam G.J., Cha K., Andalibi A., Lim D.J. Spiral ligament fibrocytes release chemokines in response to otitis media pathogens. Acta Otolaryngol. 2006, 126(6):564-569.
49. Moon S.K., Woo J.I., Lee H.Y., Park R., Shimada J., Pan H., Gellibolian R., Lim D.J. Toll-like receptor 2-dependent NF-kappa B activation is involved in nontypeable Haemophilus influenzae-induced monocyte chemotactic protein 1 up-regulation in the spiral ligament fibrocytes of the inner ear. Infect. Immun. 2007, 75(7):3361-3372.
50. Mori A., Ishii T., Kuroki T., Shigeta N., Sakamoto K., Nakahara T., Ishii K. The prostanoid EP(2) receptor agonist ONO-AE1-259-01 protects against glutamate-induced neurotoxicity in rat retina. Eur. J. Pharmacol. 2009, 616:64-67.
51. Nakashima T., Naganawa S., Sone M., Tominaga M., Hayashi H., Yamamoto H., Liu X., Nuttall A.L. Disorders of cochlear blood flow. Brain Res. Brain Res. Rev. 2003, 43(1):17-28.
52. Nakashima T., Kuno K., Yanagita N. Evaluation of prostaglandin E1 therapy for sudden deafness. Laryngoscope 1989, 99:542-546.
53. Ogawa K., Takei S., Inoue Y., Kanzaki J. Effect of prostaglandin E1 on idiopathic sudden sensorineural hearing loss: a double-blinded clinical study. Otol Neurotol 2002, 23:665-668.
54. Okano T., Nakagawa T., Kita T., Kada S., Yoshimoto M., Nakahata T., Ito J. Bone marrow-derived cells expressing Iba1 are constitutively present as resident tissue macrophages in the mouse cochlea. J. Neurosci. Res. 2008, 86(8):1758-1767.
55. Park J.Y., Pillinger M.H., Abramson S.B. Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin. Immunol. 2006, 119:229-240.
56. Picciotti P.M., Fetoni A.R., Paludetti G., Wolf F.I., Torsello A., Troiani D., Ferraresi A., Pola R., Sergi B. Vascular endothelial growth factor (VEGF) expression in noise-induced hearing loss. Hear Res. 2006, 214:76-83.
57. Puel J.L., Ruel J., Gervais d'Aldin C., Pujol R. Excitotoxicity and repair of cochlear synapses after noise-trauma induced hearing loss. Neuroreport 1998, 19(9):2109-2114.
58. Pujol R., Puel J.L., Eybalin M. Implication of non-NMDA and NMDA receptors in cochlear ischemia. Neuroreport 1992, 13(4):299-302.
59. Rhee C.K., Park Y.S., Jung T.T., Park C.I. Effects of leukotrienes and prostaglandins on cochlear blood flow in the chinchilla. Eur. Arch. Otorhinolaryngol. 1999, 256:479-483.
60. Rothwell N.J., Luheshi G.N. Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci. 2000, 23(12):618-625.
61. Saleem S., Li R.C., Wei G., Dore S. Effects of EP1 receptor on cerebral blood flow in the middle cerebral artery occlusion model of stroke in mice. J. Neurosci. Res. 2007, 85(11):2433-2440.
62. Sato E., Shick H.E., Ransohoff R.M., Hirose K. Repopulation of cochlear macrophages in murine hematopoietic progenitor cell chimeras: the role of CX3CR1. J. Comp. Neurol. 2008, 506(6):930-942.
63. Selivanova O., Heinrich U.R., Brieger J., Feltens R., Mann W. Fast alterations of vascular endothelial growth factor (VEGF) expression and that of its receptors (Flt-1, Flk-1 and Neuropilin) in the cochlea of guinea pigs after moderate noise exposure. Eur. Arch. Otorhinolaryngol. 2007, 264:121-128.
64. Shi J., Johansson J., Woodling N.S., Wang Q., Montine T.J., Andreasson K. The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J. Immunol. 2010, 184:7207-7218.
65. Simmons D.L., Botting R.M., Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 2004, 56:387-437.
66. Smith W.L., DeWitt D.L., Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 2000, 69:145-182.
67. Stjernschantz J., Wentzel P., Rask-Andersen H. Localization of prostanoid receptors and cyclo-oxygenase enzymes in guinea pig and human cochlea. Hear Res. 2004, 197:65-73.
68. Sugimoto Y., Narumiya S. Prostaglandin E receptors. J. Biol. Chem. 2007, 282:11613-11617.
69. Tai H.H., Cho H., Tong M., Ding Y. NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions. Curr. Pharm. Des 2006, 12:955-962.
70. Takahashi M., Ota S., Hata Y., Mikami Y., Azuma N., Nakamura T., Terano A., Omata M. Hepatocyte growth factor as a key to modulate anti-ulcer action of prostaglandins in stomach. J. Clin. Invest. 1996, 98(11):2604-2611.
71. Tominaga M., Yamamoto H., Sone M., Teranishi M.A., Nakashima T. Response of cochlear blood flow to prostaglandin E1 applied topically to the round window. Acta Otolaryngol. 2006, 126:232-236.
72. Umemura T., Harada N., Kitamura T., Ishikura H., Okajima K. Limaprost reduces motor disturbances by increasing the production of insulin-like growth factor I in rats subjected to spinal cord injury. Transl Res. 2010, 156(5):292-301.
73. Umemura K., Nakashima M. Effect of prostaglandin E1 on the rat inner ear microvascular thrombosis. Gen. Pharmacol. 1997, 128(2):221-224.
74. Wang M.T., Honn K.V., Nie D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metast Rev. 2007, 26:525-534.
75. Weiss T.W., Mehrabi M.R., Kaun C., Zorn G., Kastl S.P., Speidl W.S., Pfaffenberger S., Rega G., Glogar H.D., Maurer G., Pacher R., Huber K., Wojta J. Prostaglandin E1 induces vascular endothelial growth factor-1 in human adult cardiac myocytes but not in human adult cardiac fibroblasts via a cAMP-dependent mechanism. Mol. Cell Cardiol. 2004, 36:539-546.
76. Yamane H., Nakai Y., Konishi K., Sakamoto H., Matsuda Y., Iguchi H. Strial circulation impairment due to acoustic trauma. Acta Otolaryngol. 1991, 111(1):85-93.
77. Yao C., Sakata D., Esaki Y., Li Y., Matsuoka T., Kuroiwa K., Sugimoto Y., Narumiya S. Prostaglandin E(2)-EP4 signaling promotes immune inflammation through T(H)1 cell differentiation and T(H)17 cell expansion. Nat. Med. 2009, 15:633-640.
78. Ziegler E.A., Brieger J., Heinrich U.R., Mann W.J. Immunohistochemical localization of cyclooxygenase isoforms in the organ of corti and the spiral ganglion cells of guinea pig cochlea. ORL J. Otorhinolaryngol. Relat. Spec. 2004, 66:297-301.
79. Zhang J., Rivest S. Distribution, regulation and colocalization of the genes encoding the EP2- and EP4-PGE2 receptors in the rat brain and neuronal responses to systemic inflammation. Eur. J. Neurosci. 1999, 11(8):2651-2668.
80. Zhu C.L., Cao Y.H., Zhang R., Song Y., Liu W.Y., Pan F., Li Y., Zhu Y., Liu F., Wu J.G. Stimulatory effect of LPS and feedback effect of PGE2 on IL-27 production. Scand. J. Immunol. 2010, 72(6):469-475.
81. Zhuo X.L., Wang Y., Zhuo W.L., Zhang X.Y. Is the application of prostaglandin E1 effective for the treatment of sudden hearing loss? An evidence-based meta-analysis. J. Int. Med. Res. 2008, 36:467-470.